(Q29938707)

English

ABL1 BCR::ABL F359C

genetic variant

F359C
F378C
PHE359CYS
RS1057519775
BCR-ABL F359C
BCR-ABL PHE359CYS
BCR-ABL1 F359C
BCR-ABL1 PHE359CYS
BCR::ABL F359C

In more languages

default values for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

transcript fusion

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

human chromosome 9

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

133748415

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

133748415

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

positive therapeutic predictor for

medical condition treated

chronic myeloid leukemia

determination method

CGI Evidence Clinical Practice

1 reference

Cancer Biomarkers database

22 April 2018

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

medical condition treated

chronic myeloid leukemia

determination method

CGI Evidence Clinical Practice

1 reference

Cancer Biomarkers database

22 April 2018

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

negative therapeutic predictor for

imatinib mesylate

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2854

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2854

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

dasatinib monohydrate

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4482

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4480

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

dasatinib monohydrate

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4481

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

dasatinib monohydrate

determination method

CIViC evidence level C

CIViC 4-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4483

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

imatinib mesylate

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6233

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6233

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

imatinib mesylate / nilotinib combination therapy

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6239

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_005157.5:c.1076T>G

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

NP_005148.2:p.Phe359Cys

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

NC_000009.11:g.133748415T>G

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

ENST00000318560.5:c.1076T>G

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/1184

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29938707&oldid=2014805695"